WSI Co., Ltd.
Financials
Valuation Metrics
WSI Co., Ltd.'s Market Cap is ₩491B. At end of 2025 it was ₩1218B. Ranked #1783 of 2,421 in KR market (top 74%), #1089 of 1,640 on KOSDAQ (top 66%), #71 of 96 in Health Care Equipment & Services (top 74%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 49.07B KRW | KR#1,783/2,421 Sec#71/96 |
| Revenue | 50.77B KRW | KR#1,781/2,421 Sec#53/96 |
| Net Income | -1.13B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 88.94B KRW | KR#1,871/2,421 Sec#57/96 |
| Net Assets | 63.51B KRW | KR#1,752/2,421 Sec#54/96 |
| Employees | 33 | KR#2,182/2,421 Sec#87/96 |
| Value | ||
| P/B | 0.77x | KR#1,222/2,421 Sec#26/96 |
| P/S | 0.97x | KR#1,367/2,421 Sec#24/96 |
| EV/EBITDA | 24.11x | KR#1,098/2,421 Sec#37/96 |
| FCF Yield | 4.40% | KR#890/2,421 Sec#24/96 |
| Profitability | ||
| ROE | -1.78% | KR#1,674/2,421 Sec#57/96 |
| ROA | -1.27% | KR#1,700/2,421 Sec#57/96 |
| Op. Margin | 5.14% | KR#947/2,421 Sec#39/96 |
| Revenue Growth | 1.62% | KR#1,416/2,421 Sec#72/96 |
| Financial Health | ||
| Debt Ratio | 40.04% | KR#788/2,421 Sec#41/96 |
| Total Debt | 21.50B KRW | KR#1,353/2,421 Sec#39/96 |
| FCF | 2.16B KRW | KR#1,071/2,421 Sec#31/96 |
| Cash | 7.70B KRW | KR#1,833/2,421 Sec#61/96 |
| Current Ratio | 2.74x | KR#621/2,421 Sec#37/96 |
| Net Debt/EBITDA | 5.29x | KR#1,040/2,421 Sec#39/96 |
| Performance | ||
| 1Y Return | -36.59% | KR#1,753/2,421 Sec#55/96 |
| 1M Return | -4.21% | KR#1,721/2,421 Sec#56/96 |
| From 52W High | -76.36% | KR#2,309/2,421 Sec#90/96 |
| 1Y MDD | -74.14% | KR#2,150/2,421 Sec#81/96 |
| Trading | ||
| Volume | 235,801 shares | KR#426/2,421 Sec#16/96 |
| Trading Value | 274.0M KRW | KR#1,156/2,421 Sec#43/96 |
| Foreign Own. | 5.56% | KR#784/2,421 Sec#24/96 |
| Per Share | ||
| EPS | -27 KRW | KR—/2,421 Sec—/96 |
| BPS | 1,530 KRW | KR#2,185/2,421 Sec#78/96 |
Company Info
Established in 2016, WSI was listed on KOSDAQ in 2020 following its merger with IBKS No.10 Special Purpose Acquisition Company. The company's main business is the distribution of spinal and joint medical devices. In 2024, WSI acquired a 67% stake in pharmaceutical company Introbio Pharma, adding pharmaceutical manufacturing and R&D, with plans to acquire an additional 10% in the first half of 2025. Headquartered in Songpa-gu, Seoul, WSI is also entering the cardiovascular interventional medical device market from 2024 through collaboration with a global cardiac disease medical device company.